iRhythm announced that it plans to use Epic’s Aura platform to streamline access to its Zio long-term monitoring and telemetry services. With this collaboration, iRhythm can make Zio more readily available to healthcare providers using Epic. That also applies to the more than 250 million patients in the U.S. who have a health record in […]
iRhythm Technologies Inc.
iRhythm stock dips on mixed Q4 as guidance ‘may disappoint’ investors
iRhythm Technologies shares took a hit today on third-quarter results that came in mixed compared to the consensus forecast. Shares of IRTC fell 5.5% at $108.75 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — remained even. The San Francisco-based heart monitoring technology […]
iRhythm releases strong Q4 prelims, strengthens balance sheet
iRhythm Technologies today released a solid preliminary earnings update that included projections of up to 20% revenue growth in 2024. The wearable cardiac monitors developer saw IRTC shares jump more than 7% in value to $112.91 apiece by the close of trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical […]
iRhythm wins CE mark for next-gen Zio ECG system, Zeus software
iRhythm Technologies announced today that it received CE mark for its Zio system and its supporting Zeus AI algorithm. San Francisco-based iRhythm designed the next-generation Zio long-term ambulatory cardiac monitor to detect potential cardiac arrhythmias. Zeus, the company’s advanced, deep-learned AI algorithm, supports the capture and analysis of ECG data recorded by Zio. The company […]
iRhythm faces another subpoena from the DOJ
Wearable cardiac monitor developer iRhythm disclosed its third subpoena in more than two years from federal investigators. The news raised some questions from analysts, who were otherwise positive about iRhythm’s first-quarter earnings report yesterday evening. San Francisco–based iRhythm said that on April 4, it received a subpoena duces tecum from the U.S. Department of Justice […]
Real-world study backs iRhythm Zio XT
iRhythm Technologies (Nasdaq:IRTC) today announced findings supporting its Zio XT wearable heart monitoring technology. San Francisco-based iRhythm presented multiple new studies at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC). The Camelot study compared effectiveness of ambulatory monitors for arrhythmia diagnosis. It demonstrated that long-term continuous monitoring […]
iRhythm sees years of sustainable growth
Wearable cardiac monitor developer iRhythm (NASDAQ:IRTC) saw its stock shoot up today, a day after reporting positive Q4 2022 news. IRTC shares were up more than 10% at $97.26 apiece by midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 8%. San Francisco–based […]
iRhythm wants to be a $1 billion a year company in 5 years
iRhythm Technologies (Nasdaq:IRTC) officials think their company’s wearable heart monitoring tech could serve millions more patients, tripling company revenue to more than $1 billion by 2027. That was a big takeaway from the company’s 2022 Analyst & Investor Day news release today. “Our technology platform is well suited to meet the needs of an evolving […]
iRhythm Technologies stock jumps on Q2 earnings beat
iRhythm Technologies (Nasdaq:IRTC) posted second-quarter results that beat the consensus forecast on Wall Street. Yesterday evening, the San Francisco–based developer of the Zio ambulatory cardiac monitor reported a loss of $23.9 million, or $0.80 per share, on sales of $102.1 million for the quarter ended June 30, 2022. Revenue was up 25.6% year-over-year, primarily driven […]
Studies show that iRhythm’s Zio detects AFib early, prevents hospital admissions
iRhythm Technologies (Nasdaq:IRTC) announced results of multiple studies supporting the use of its Zio technology in detecting AFib. San Francisco-based iRhythm presented the results of three clinical research studies at The American College of Cardiology’s 71st Annual Scientific Session & Expo. According to a news release, the studies further validate Zio as an option for […]
Former CEO Kevin King to retire from iRhythm’s board of directors
iRhythm Technologies (Nasdaq:IRTC) announced today that Kevin King will retire from the company’s board of directors. King joined San Francisco–based iRhythm’s board in July 2012 and served as the company’s president and CEO from then until January 2021. “On behalf of the entire iRhythm team, I would like to thank Kevin for his contributions over […]
